EGFR and non-small cell lung carcinoma: Early results have confirmed ORRs in six of 18 patients (ORR 33.3%), including one patient with NSCLC harboring EGFR mutation and both EGFR and MET gene amplification who progressed after treatment with osimertinib and achieved a partial response after five cycles of MRTX1719 [165].